Review: Natalizumab in the treatment of multiple sclerosis (Q34409340)

2 August 2017

1 reference

title

Natalizumab in the treatment of multiple sclerosis (English)

1 reference

2 August 2017

Review: Natalizumab in the treatment of multiple sclerosis (English)

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

20 November 2024

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21180646

20 November 2024

1

Ozgür Yaldizli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21180646

20 November 2024

author name string

Norman Putzki

series ordinal

2

1 reference

2 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21180646

20 November 2024

publication date

1 March 2009

1 reference

2 August 2017

March 2009

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21180646

full work available at URL

20 November 2024

https://journals.sagepub.com/doi/pdf/10.1177/1756285608101861

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21180646

https://europepmc.org/articles/PMC3002624

20 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21180646

https://europepmc.org/articles/PMC3002624?pdf=render

20 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21180646

https://doi.org/10.1177/1756285608101861

20 November 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21180646

https://journals.sagepub.com/doi/pdf/10.1177/1756285608101861

20 November 2024

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

Therapeutic advances in neurological disorders

20 November 2024

published in

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

115-128

1 reference

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy in transplant recipients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Visual symptoms after lung transplantation: a case of progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Osteopontin is a ligand for the alpha4beta1 integrin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Review: JC virus infection of lymphocytes--revisited

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

The pathophysiologic role of alpha 4 integrins in vivo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy. A case report and review of the literature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy: immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+T lymphocytes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Detection of JC virus in the brains of aged patients without progressive multifocal leukoencephalopathy by the polymerase chain reaction and Southern hybridization analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Evidence of human polyomavirus BK and JC infection in normal brain tissue

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient.

6 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Making progress on the natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Age at disability milestones in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Allergic and nonallergic delayed infusion reactions during natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

JC virus DNA in cerebrospinal fluid of human immunodeficiency virus—infected patients: Predictive value for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Melanoma complicating treatment with natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Natalizumab effects on immune cell responses in multiple sclerosis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leucoencephalopathy and immunosuppression.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Diagnosis of progressive multifocal leukoencephalopathy by stereotactic brain biopsy utilizing immunohistochemistry and the polymerase chain reaction

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

α4Integrins as Therapeutic Targets in Autoimmune Disease

27 October 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285608101861

Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002624

Progressive multifocal leukoencephalopathy

27 October 2018

1 reference

12 December 2020

More on melanoma with transdifferentiation

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy and cryptococcal meningitis with systemic lupus erythematosus and thymoma

1 reference

12 December 2020

Case Report Simultaneous fungal and viral infection of the central nervous system

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis

1 reference

12 December 2020

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

12 December 2020

Unsuccessful treatment with cidofovir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis and polymyositis

1 reference

12 December 2020

Reply to "'Thinking without thinking' about natalizumab and PML"

1 reference

12 December 2020

Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation

1 reference

12 December 2020

Engineering antibodies for therapy

1 reference

12 December 2020

Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in myasthenia gravis

1 reference

12 December 2020

Is natalizumab overshooting its rebound?

1 reference

12 December 2020

Natalizumab: immune effects and implications for therapy

1 reference

12 December 2020

Annals of the Rheumatic Diseases

14

63

112

Cuevas, L.A.

2004

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

The Journal of Rheumatology

20 November 2024

55

22

1593

Morgenstern, L.B.

1995

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

Acta Pathologica Japonica

20 November 2024

59

32

333

Nagashima, K.

1982

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

The Journal of Rheumatology

20 November 2024

70

22

777

Rankin, E.

1995

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

20 November 2024

series ordinal

86

1 reference

https://api.crossref.org/works/10.1177/1756285608101861

20 November 2024

Identifiers

1 reference

2 August 2017

1 reference

2 August 2017

1 reference